Clinical Trial Update: Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating regorafenib in combination with raltitrexed as a third-line treatment for advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Raltitrexed (Raltitrexed)
• Regorafenib (regorafenib)

Snippet

Sponsor: China Medical University, China | Conditions: Regorafenib, Raltitrexed | Phase 1, Phase 2 | Status: UNKNOWN